https://erksignaling.com/index.....php/indication-of-c
While SOLO-1 only included BRCAm patients, PRIMA, VELIA, and PAOLA-1 enrolled broader patient communities. The magnitude of benefit of PARPi in these scientific studies ended up being consistently best within the BRCAm clients (germline or cyst). PARPi therapy also enhanced PFS in the HRD cohort but to an inferior degree compared to patients with BRCAm. In secondary analyses, the entire impact of PARPi treatment in HR proficient patients, which make up about 50% o
Like
Comment
Share
